LENZ Therapeutics shares 3rd quarter financial results

LENZ Therapeutics, Inc. the pharmaceutical company focused on the commercialization of recently FDA-approved VIZZ (aceclidine ophthalmic solution) 1.44%, has announced financial results for the third quarter ending September 30, 2025, as well as recent corporate highlights. Highlighted among those was the FDA approval in late July of VIZZ, an aceclidine-based eye drop for the treatment of presbyopia in adults, as well as its commercial product launch initiated in October. In sharing yesterday’s financial and corporate updates, the company reported pro forma cash, cash equivalents and marketable securities of approximately $324.0 million as of September 30, 2025, which the company said is anticipated to fund operations to post-launch positive cash flow.

“We are very pleased with the first weeks of the VIZZ launch as we introduce our exciting new solution for the treatment of presbyopia into the marketplace and have been highly encouraged by the enthusiasm from the ECP community, as evidenced by the over 2,500 unique prescribers and impressively over 5,000 prescriptions filled through October,” said Eef Schimmelpennink, president and chief executive officer of LENZ Therapeutics, referencing further data that demonstrated that 40 percent of ECPs prescribed VIZZ multiple times, resulting in over 5,000 prescriptions filled through October 2025. “Early patient feedback has been very positive, and it is undisputed that VIZZ is highly effective at restoring near vision with rapid onset and long duration.”

The company further reported that selling, general and administrative expenses increased to $27.6 million and $51.5 million for the three and nine months ended September 30, 2025, respectively, compared with $6.5 million and $19.5 million during the same periods in 2024, primarily driven by what the company identified as increases in personnel-related expenses due to a growth in headcount, including the hiring of 88-territory sales force, and pre-commercial marketing, advertising and sales infrastructure expenses as it prepared for and executed the commercial launch of VIZZ.

Research and development expenses decreased to $3.8 million for the three months ended September 30, 2025, compared with $6.5 million during the same period in 2024, the company advised. Further, research and development expenses decreased to $18.7 million for the nine months ended September 30, 2025, compared to $23.9 million during the same period in 2024, driven by what the company identified as decreases in clinical trial-related expenses. Net loss for the three and nine months ended September 30, 2025, was $16.7 million and $46.2 million, respectively, compared with a net loss of $10.2 million and $37.1 million, during the same periods in 2024.

The company advised that it anticipates broad product availability of VIZZ in mid-Q4 2025, with the commercial launch focus in the fourth quarter on awareness, confidence and willingness to prescribe by ECPs proving effective:

• Awareness for VIZZ was 90 percent in October 2025 among surveyed ECPs, driven by approximately 17,000 unique ECPs detailed and over 5 million digital campaign impressions since approval, consistently over 13,000 ECP sales calls on a rolling 4-week basis by our 88-territory sales force and supported by significant commercial presence at multiple major industry conferences.
  
• Confidence in VIZZ driven by positive real-world ECP experience; nearly 70,000 product samples provided to approximately 7,000 ECP offices and over 9,000 ECP opt-in elections to Find-a-Doctor on VIZZ.com through October 2025.
  
• Willingness to Prescribe VIZZ has rapidly increased with over 2,500 unique prescribing ECPs, already 40 percent of which have prescribed multiple times, resulting in over 5,000 prescriptions filled through October 2025.

“The months ahead promise to continue to be very exciting,” said Schimmelpennink, who also highlighted the company’s newly announced partnership with Sarah Jessica Parker as a direct-to-consumer campaign spokesperson, slated to launch in Q1 2026.